Study Summary
This trial is to study the effects of a new drug, remternetug, in people with early Alzheimer's disease.
- Alzheimer's Disease
Video Summary
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
0 Primary · 5 Secondary · Reporting Duration: Up to Week 52
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
5 Treatment Groups
Remternetug (SC)
1 of 5
Open-Label Addenda Remternetug (SC)
1 of 5
Remternetug (IV)
1 of 5
Open-Label Addenda Remternetug (IV)
1 of 5
Placebo
1 of 5
Experimental Treatment
Non-Treatment Group
600 Total Participants · 5 Treatment Groups
Primary Treatment: Remternetug (SC) · Has Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 60 - 85 · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
What state do they live in?
Texas | 42.9% |
Pennsylvania | 28.6% |
New Hampshire | 14.3% |
Other | 14.3% |
How old are they?
18 - 65 | 100.0% |
What site did they apply to?
Neuro-Pain Medical Center | 25.0% |
MedVadis Research Corporation | 25.0% |
NeuroScience Research Center | 25.0% |
Other | 25.0% |
What portion of applicants met pre-screening criteria?
Did not meet criteria | 40.0% |
Met criteria | 60.0% |
Why did patients apply to this trial?
- "I have called a number of trials. Most recently this month for Simufilam but the screening tester said my MMSE score was to low at 12/30 to enter the study. My current clinics most recent MoCA score was 15/30. I am hoping to get in a trial for something that might help as I was diagnosed over 3 years ago and have a strong family history. I am other wise very physically healthy."
- "I know that I have pre-clinical Alzheimer's but I do not know my MMSE score. I am in the process of getting my own neurologist to help me navigate the clinical trial space. I would like to participate in a preventative or early Alzheimer's trial. With all the new biomarkers available it makes defining early Alzheimer's more difficult - for example, do you have to have measured cognitive decline if you have elevated amyloid plaque in your brain and intermediate tau?"
What questions have other patients asked about this trial?
- "If the primary objective of the trial is reduced amyloid plaque then why does there need to be clinical evidence of cognitive decline. If I am diagnosed with pre-clinical Alzheimer's disease then do I have Alzheimer's?"
How many prior treatments have patients received?
0 | 50.0% |
1 | 25.0% |
3+ | 25.0% |
Frequently Asked Questions
Does this research rely on a geriatric patient base?
"According to the eligibility requirements for this clinical trial, the minimum age for participation is 60 and the maximum age is 85." - Anonymous Online Contributor
How many individuals can join this research project?
"The pharmaceutical company Eli Lilly and Company is sponsoring a clinical trial that requires 400 individuals that meet the necessary inclusion criteria. The trial will take place in Columbus Memory Center, LLC in Columbus, Georgia and Summit Headlands in Portland, Oregon." - Anonymous Online Contributor
Please tell us how many hospitals are participating in this experiment.
"There are many locations across the country where this trial is being conducted, some of which include Columbus Memory Center, LLC in Columbus, Georgia, Summit Headlands in Portland, Oregon, and The University of Texas Health Science Center at Houston in Sugar Land, Texas." - Anonymous Online Contributor
Are we still taking volunteers for this research project?
"The online database clinicaltrials.gov indicates that this trial is actively recruiting patients. The listing was created on 8/1/2022 and was last updated on 10/17/2022." - Anonymous Online Contributor
What is the official decision from the FDA about Remternetug (SC)?
"Remternetug (SC) is a Phase 3 trial medication, meaning that it has some efficacy data to support its safety, which our team at Power rates as a 3." - Anonymous Online Contributor
If I meet the qualifications, may I join this clinical trial?
"This study, which is looking for 400 patients that suffer from Alzheimer's disease, has the following age requirement: 60-85. Most notably, candidates must meet the following criteria: Gradual and progressive change in cognitive function ≥6 months prior to screening., A Mini-Mental (MMSE) score of 20 to 28 (inclusive) at screening., Have a reliable study partner who will provide written informed consent to participate and is in frequent contact with the participant., Have adequate literacy, vision, and hearing for the neuropsychological testing in the opinion of the investigator at the time of screening., Are reliable and willing to make themselves available" - Anonymous Online Contributor